PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Haw Par's PE Ratio without NRI is 9.75. Haw Par's 5-Year EBITDA growth rate is 0.50%. Therefore, Haw Par's PEG Ratio for today is 19.51.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Haw Par's PEG Ratio or its related term are showing as below:
HAWPF'
s PEG Ratio Range Over the Past 10 Years
Min: 0.9 Med: 2.46 Max: 20.16
Current: 20.08
During the past 13 years, Haw Par's highest PEG Ratio was 20.16. The lowest was 0.90. And the median was 2.46.
HAWPF's PEG Ratio is ranked worse than 96.25% of 373
companies
in the Drug Manufacturers industry
Industry Median: 1.71
vs HAWPF: 20.08
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Haw Par PEG Ratio Historical Data
The historical data trend for Haw Par's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Haw Par's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par's PEG Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Haw Par's PEG Ratio falls into.
Haw Par PEG Ratio Calculation
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio.
The ratio we use is the 5-Year EBITDA growth rate.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Haw Par (OTCPK:HAWPF) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Haw Par PEG Ratio Related Terms
Thank you for viewing the detailed overview of Haw Par's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, and Others segment. The company generates maximum revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates a majority of its revenue from the ASEAN countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HAWPF has been successfully added to your 